TY  - JOUR
AU  - van der Weijst, Lotte
AU  - Azria, David
AU  - Berkovic, Patrick
AU  - Boisselier, Pierre
AU  - Briers, Erik
AU  - Bultijnck, Renée
AU  - Chang-Claude, Jenny
AU  - Choudhury, Ananya
AU  - Defraene, Gilles
AU  - Demontois, Sylvian
AU  - Elliott, Rebecca M
AU  - Ennis, Dawn
AU  - Faivre-Finn, Corinne
AU  - Franceschini, Marzia
AU  - Giandini, Tommaso
AU  - Giraldo, Alexandra
AU  - Gutiérrez-Enríquez, Sara
AU  - Herskind, Carsten
AU  - Higginson, Daniel S
AU  - Kerns, Sarah L
AU  - Johnson, Kerstie
AU  - Lambrecht, Maarten
AU  - Lang, Philippe
AU  - Ramos, Mónica
AU  - Rancati, Tiziana
AU  - Rimner, Andreas
AU  - Rosenstein, Barry S
AU  - De Ruysscher, Dirk
AU  - Salem, Ahmed
AU  - Sangalli, Claudia
AU  - Seibold, Petra
AU  - Sosa Fajardo, Paloma
AU  - Sperk, Elena
AU  - Stobart, Hilary
AU  - Summersgill, Holly
AU  - Surmont, Veerle
AU  - Symonds, Paul
AU  - Taboada-Valladares, Begoña
AU  - Talbot, Christopher J
AU  - Vega, Ana
AU  - Veldeman, Liv
AU  - Veldwijk, Marlon R
AU  - Ward, Tim
AU  - Webb, Adam
AU  - West, Catharine M L
AU  - Lievens, Yolande
TI  - The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.
JO  - Radiotherapy and oncology
VL  - 176
SN  - 0167-8140
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2022-02329
SP  - 127-137
PY  - 2022
N1  - 2022 Oct 3;176:127-137
AB  - To investigate the association between clinician-scored toxicities and patient-reported health-related quality of life (HRQoL), in early-stage (ES-) and locally-advanced (LA-) non-small cell lung cancer (NSCLC) patients receiving loco-regional radiotherapy, included in the international real-world REQUITE study.Clinicians scored eleven radiotherapy-related toxicities (and baseline symptoms) with the Common Terminology Criteria for Adverse Events version 4. HRQoL was assessed with the European Organization for Research and Treatment of Cancer core HRQoL questionnaire (EORTC-QLQ-C30). Statistical analyses used the mixed-model method; statistical significance was set at p=0.01. Analyses were performed for baseline and subsequent time points up to 2 years after radiotherapy and per treatment modality, radiotherapy technique and disease stage.Data of 435 patients were analysed. Pre-treatment, overall symptoms, dyspnea, chest wall pain, dysphagia and cough impacted overall HRQoL and specific domains. At subsequent time points, cough and dysphagia were overtaken by pericarditis in affecting HRQoL. Toxicities during concurrent chemo-radiotherapy and 3-dimensional radiotherapy had the most impact on HRQoL. Conversely, toxicities in sequential chemo-radiotherapy and SBRT had limited impact on patients' HRQoL. Stage impacts the correlations: LA-NSCLC patients are more adversely affected by toxicity than ES-NSCLC patients, mimicking the results of radiotherapy technique and treatment modality.Pre-treatment symptoms and acute/late toxicities variously impact HRQoL of ES- and LA-NSCLC patients undergoing different treatment approaches and radiotherapy techniques. Throughout the disease, dyspnea seems crucial in this association, highlighting the additional effect of co-existing comorbidities. Our data call for optimized radiotherapy limiting toxicities that may affect patients' HRQoL.
KW  - Health-related quality of life (Other)
KW  - association (Other)
KW  - non-small cell lung cancer (Other)
KW  - patient-reported outcomes (Other)
KW  - radiotherapy (Other)
KW  - technique (Other)
KW  - toxicity (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36195214
DO  - DOI:10.1016/j.radonc.2022.09.020
UR  - https://inrepo02.dkfz.de/record/181959
ER  -